ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements with these filters
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹271 Cr (+31.6% YoY) and net profit of ₹24.6 Cr (+2.9% YoY) for Q2 FY27.
Krsnaa Diagnostics intimated that its board will meet on November 2, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. No financial figures are disclosed in this notice.
Krsnaa Diagnostics has formed a strategic AI collaboration with AZmed to integrate AI radiology solutions for enhanced operational efficiency and scalable diagnostic reporting.
Krsnaa Diagnostics Ltd submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Krsnaa Diagnostics has allotted 16,21,000 convertible warrants to 2 investors at a price of Rs. 566 per warrant.
Krsnaa Diagnostics allotted 16.21 lakh convertible warrants to promoter entities at ₹566 per warrant. The company collected ₹22.94 Crore as 25% upfront subscription money.
Krsnaa Diagnostics received in-principle approval from BSE and NSE to issue 16.21 lakh convertible warrants at Rs. 566 per share to the promoter group.
Krsnaa Diagnostics Limited has appointed M/s Kirtane & Pandit LLP as Statutory Auditors for a five-year term. The appointment is effective from April 1, 2026.
Krsnaa Diagnostics Limited has appointed M/s Kirtane & Pandit LLP as its Statutory Auditor for a five-year term. The appointment was approved at the 16th Annual General Meeting.
Krsnaa Diagnostics received board approval to sell identified diagnostic equipment for an aggregate consideration of up to ₹120 crore, aiming to optimize its asset portfolio.
Krsnaa Diagnostics Limited conducted its 16th Annual General Meeting on September 28, 2026. Shareholders considered resolutions including the adoption of financial statements and a final dividend declaration.
Krsnaa Diagnostics Ltd reported the successful passing of a special resolution via postal ballot approving the issuance of up to 16,21,000 convertible warrants to promoters.
Krsnaa Diagnostics executed a 15-year concession agreement with the Punjab Government to develop and operate PET-CT diagnostic facilities at four government hospitals.
Krsnaa Diagnostics received tax appellate orders for AY 2017-24 with aggregate disputed demands of ₹62.69 Crore. The company plans to file further appeals.
Krsnaa Diagnostics has filed its Business Responsibility and Sustainability Report for the financial year 2025-26 as required by regulatory listing obligations.
Krsnaa Diagnostics Limited has submitted the notice of its 16th Annual General Meeting, scheduled for September 28, 2026, along with the Annual Report for 2025-26.
Krsnaa Diagnostics issued a corrigendum to its Postal Ballot notice, providing additional disclosures regarding the proposed preferential issue of share warrants to promoters.
Krsnaa Diagnostics received an income tax rectification order for AY 2022-23, resulting in an additional demand of Rs. 12.10 Crore. The company intends to appeal.
Krsnaa Diagnostics will hold a postal ballot to seek shareholder approval for a preferential issue of convertible warrants totaling ₹91.75 Crore.
Krsnaa Diagnostics will seek shareholder approval via postal ballot to issue 16.21 lakh warrants to promoters at Rs. 566 per warrant, aggregating Rs. 91.75 Crore.
Krsnaa reported 22% revenue growth but suffered margin compression due to heavy front-ended costs for the Rajasthan project. Management pivots to 'long-term value' to deflect from current EBITDA and PAT dips.
Krsnaa Diagnostics reported 22% revenue growth in Q1 FY27, driven by expanding retail business and PPP project scaling, despite margin pressure from Rajasthan operationalization.
Krsnaa Diagnostics reported Q1 FY2027 revenue of ₹235.5 Crore, up 22% YoY. The Board also approved a preferential warrant issue for the Promoter Group.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹235.5 Cr (+22.0% YoY) and net profit of ₹16.6 Cr (-19.0% YoY) for Q1 FY27.